Amgen Inc. (NASDAQ:AMGN) Shares Acquired by ORG Partners LLC

ORG Partners LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.5% during the fourth quarter, HoldingsChannel reports. The fund owned 8,975 shares of the medical research company’s stock after buying an additional 41 shares during the period. ORG Partners LLC’s holdings in Amgen were worth $2,345,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the 3rd quarter worth approximately $25,000. Strategic Financial Concepts LLC acquired a new stake in Amgen in the 2nd quarter valued at about $26,000. Legacy Investment Solutions LLC purchased a new position in Amgen in the third quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen during the second quarter worth $30,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen during the 3rd quarter worth about $36,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.5 %

Shares of NASDAQ AMGN traded down $1.43 during midday trading on Friday, hitting $262.78. The stock had a trading volume of 445,615 shares, compared to its average volume of 2,663,323. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market capitalization of $141.25 billion, a price-to-earnings ratio of 33.65, a PEG ratio of 2.91 and a beta of 0.56. The company has a fifty day moving average price of $280.24 and a 200 day moving average price of $309.15.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.62%. Amgen’s dividend payout ratio (DPR) is 121.90%.

Analyst Ratings Changes

Several equities analysts have issued reports on AMGN shares. Citigroup decreased their price objective on shares of Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Bank of America reissued an “underperform” rating and set a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. UBS Group decreased their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Finally, Royal Bank of Canada cut their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.